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ABSTRACT
Serous Ovarian Cancers (SOC) are frequently resistant to programmed cell 
death. However, here we describe that these programmed death-resistant cells 
are nonetheless sensitive to agents that modulate autophagy. Cytotoxicity is not 
dependent upon apoptosis, necroptosis, or autophagy resolution. A screen of NCBI 
yielded more than one dozen FDA-approved agents displaying perturbed autophagy in 
ovarian cancer. The effects were maximized via combinatorial use of the agents that 
impinged upon distinct points of autophagy regulation. Autophagosome formation 
correlated with efficacy in vitro and the most cytotoxic two agents gave similar effects 
to a pentadrug combination that impinged upon five distinct modulators of autophagy. 
However, in a complex in vivo SOC system, the pentadrug combination outperformed 
the best two, leaving trace or no disease and with no evidence of systemic toxicity. 
Targeting the autophagy pathway in a multi-modal fashion might therefore offer a 
clinical option for treating recalcitrant SOC.
INTRODUCTION
Targeted drugs with better safety profiles than 
traditional cytotoxic chemotherapeutics are increasingly 
available in the oncologist’s armament. While use of 
single agent targeted therapies has shown only limited 
success [1–3], the lower toxicity of the drugs provides 
significant hope that logical combinations of these drugs 
may offer improved options relative to single drugs alone. 
Since each tumor might bear a fraction of cells resistant to 
any single therapy [4, 5], the use of monotherapies leaves 
resistant cells to initiate recurrent disease. Yet, problems of 
drug resistance in non-oncologic fields, including bacterial 
infection [6] and human immunodeficiency virus (HIV) 
[7], have been successfully approached with the use of 
multiple agents. Highly active antiretroviral therapy 
(HAART) was similarly developed to combat the high 
mutation rates present in HIV, and represents a remarkable 
success using three drug combinations.
In oncology, where the existing standards of care 
are highly toxic, there is little room for the addition of 
even those agents with modest toxicity. Targeting a single 
node on a signaling pathway with multiple drugs can be of 
benefit, though if drugs which target a single node are too 
similar in mechanism or chemical structure, resistance to 
one agent can confer resistance to others [8, 9]. Multinodal 
targeting may circumvent resistance, although side effects 
from such therapy are less predictable. However, the 
risk of not finding efficacious regimens to treat cancer 
is similarly high; every day this year, an average of 38 
women will die of ovarian cancer from failed therapy, 
since there are no good options to treat the recalcitrant 
disease (American Cancer Society 2015 estimates).
SOC is among the most heterogeneous cancers [10], 
which may explain its abysmal five year survival rate of 
17–39% (stage III/IV) (SEER 2004–2010 data). Early 
stage tumors are very hard to detect with high specificity 
[11], and SOC typically presents as disseminated disease. 
Standard of care chemotherapy consists of a platinum-
taxane two drug regimen and results in an initial 2-year 
remission rate of 75% [12]. About half of these patients 
will recur. Novel agents targeting SOC rarely have 
sufficient impact to advance to Phase III trials.
Autophagy has been implicated as a mechanism 
in which dormant or otherwise chemotherapy resistant 
cells survive the initial platinum-taxane regimen [13–15]. 
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However, autophagy agents have also been shown 
to induce death in SOC cell lines [16, 17]. Here, we 
examined both mode of death and cooperativity of 
the autophagy-modulating agents. While we noted an 
excellent cytotoxic effect of single agents that altered 
autophagy in vitro, the combinatorial use of relatively low 
toxicity agents revealed dramatic increases in cytotoxic 
efficacy in mouse tumor models. Based on these results, 
we suggest that it may be possible to create a combination 
that is able to treat the inherent heterogeneity of the tumor 
while harboring a favorable safety profile.
RESULTS
Identification of drugs that modulate autophagy
Targeting autophagy has been described as a 
method to enhance killing of subpopulations of SOC cells 
resistant to chemotherapy [13]. Since “autophagic death” 
can occur in parallel to classical forms of programmed 
cell death [20], such as apoptosis and/or necroptosis, and 
apoptotic and necroptotic initiation proteins are frequently 
inactive in SOC [18], we sought to investigate the mode 
of cell killing by agents which impact autophagy, with the 
hope of possible rapid translation to logical combination 
therapies within a clinical milieu.
In a filtered search using the terms “autophagy” 
and “ovarian cancer” in PubMed and Google Scholar, 26 
agents were found to impact autophagy in ovarian cancer 
(Table 1). Among these, 13 are FDA-approved and with 
a modest adverse event profile in patients (Figure 1). 
Surprisingly, however, these agents influence a repertoire 
of cellular processes including cellular metabolism, 
protein phosphorylation, proteotoxic stress, and lysosome 
acidification. This variation in target pathways suggests 
a broad interaction between SOC biological processes 
and autophagy. Within each molecular process, we then 
selected the drug with the lowest overall adverse events 
for further study. One was the DNA-targeted drug 
doxorubicin, which indirectly activates autophagy in 
response to genotoxic stress. The other five drugs were the 
ER stressor nelfinavir, the lysosomal acidification inhibitor 
chloroquine, the mTORC1 inhibitor rapamycin, the anti-
diabetic metformin, and the Src family kinase inhibitor 
dasatinib (Figure 1).
Autophagy-modulating agents do not induce 
classical cell death pathways
“Autophagic death” occurs via several mechanisms, 
yet it has been suggested to be a misnomer, since 
autophagy often accompanies other forms of cell death 
[21]. It therefore becomes important to distinguish 
between causation, such as when autophagosomes act 
as an intracellular scaffold for caspase-8 activation [22], 
vs. simple co-occurrence of programmed cell death and 
autophagy. In many cases, the autophagic response is 
elicited to try to correct the stress inducing programmed 
cell death. One indicator of cellular stress is sequestosome, 
or p62, an adaptor that targets ubiquinated proteins to 
autophagosomes, though it may also recruit caspase-8 [23] 
or RIPK1 [24] as part of apoptotic or necroptotic pathways 
respectively (Figure 1).
To evaluate cell death in the context of autophagy 
inducing drugs, we drugged OVCAR3 cells within the 
range found in monotherapy treated patients’ blood 
(Table 2). Although many ovarian cancer cell lines are not 
genetically representative of SOC [25], the OVCAR3 line 
closely aligns with TCGA-documented SOC, has a deep 
accompanying dataset (>1000 publications), and behavior 
similar to cisplatin resistant cells derived from recurrent 
patients [26]. In agreement with prior literature, we noted 
an induction of autophagosomes upon drug addition. 
This was indicated by an increase in steady state LC3-II 
compared to β-actin, not the LC3-II to LC3-I ratio, which 
may have confounding signals from protein turnover 
during autophagy as well as LC3-I induction independent 
of autophagic flux [27]. Interestingly, a correlation of 
LC3-II/β-actin with cell loss (p < 0.006, Figure 2A) was 
observed among four of the five drugs, while metformin 
was observed to be relatively ineffective (<5% cell loss) 
in OVCAR3 cells.
Strikingly, none of the drugs induced PARP cleavage 
(as observed in apoptosis, and sometimes in necroptosis) 
or phosphorylation of MLKL (a marker of necroptosis) 
(Figure 2B–2E). The results suggested that cell loss was 
not associated with apoptotic or necroptotic cell death. 
To investigate this further, we employed pharmacologic 
agents to directly modulate the apoptotic and necroptotic 
pathways. The inhibitor z-VAD
fmk
 blocks cysteine protease 
activity, compromising caspase activation and attenuating 
apoptosis, and can potentiate necroptosis. Necrostatin is 
an inhibitor of RIPK1 activity and blocks many forms of 
necroptosis. Necrostatin and z-VAD
fmk
 both proved able 
to modulate death induced by a small molecule antagonist 
of the IAPs (Figure 2F). In this case, z-VAD
fmk
 potentiated 
necroptotic death, while necrostatin rescued cell survival 
[26]. However, neither necrostatin nor z-VAD
fmk
 showed 
more than 10% rescue in cell loss induced by nelfinavir, 
chloroquine, dasatinib, or rapamycin (Figure 2G–2J). 
In summary, all agents which created autophagic stress, 
as represented by dasatinib, rapamycin, and nelfinavir, 
promoted cell death. However, inhibition of autophagy 
by chloroquine also promoted death. Thus, death did not 
appear to occur as a result of autophagy per se, although 
LC3-II expression increased along with cytotoxicity.
Combinatorial autophagic stresses enhance 
SOC cell death
We then tested whether combinations of different 
agents resulted in any alteration of the cell death 
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Table 1: Drugs with evidence of affecting autophagy in ovarian cancer
Most Frequent 
Adverse Events
Drug Target Ref 
(PMID)
FDA 
approved?
Patent end 
date?
Autophagy 
stage
G1–2 G3 G4 Safety 
Reference
Notes
Nelfinavir ER stress 19106637 Y No patent
Initiation, 
compensation 
for ER stress
17% - -
FDA 
(NDA 21–503)
Chloroquine Lysosome 19033662 Y No patent Clearance 2% - -
PMID 
10759574
Dasatinib Src family 20629079 Y 6/2020 Initiation 17% 5%
FDA 
(NDA 21–986)
Rapamycin mTORC1 19033662 Y No patent
Initiation and 
expansion
35% 15% 2%
PMID 
21752435*
Temsi - 
rolimus
Metformin AMPK, LKB1 21532889 Y No patent
Stem cells 
or AMPK/
LKB1/
initiation
8–13% - -
PMID 
17638715
Doxorubicin DNA 22860102 Y Equivalents Initiation 37% 11%
FDA 
(NDA 50–718)
Titanocene Y DNA 23019413 N - Initiation - - -
Carboplatin DNA 21743489* Y No patent
Initiation, 
protective 
autophagy
98%
FDA (NDA 
20–452)
*cisplatin
5-fluorouracil
DNA, ER 
stress 22684338 Y Equivalents Initiation 33% 52% 42%
FDA (NDA 
20–985)
Diindolylmethane ER Stress 22564965 N* - Initiation 0% 0% 0%
FDA (Docket 
95s0316/
sup0002)
*Supple- 
ment
3-methyladenine BECN1 24817946 N -
Initiation 
block, 
enhances 
cisplatin death
- - -
Saquinavir ER Stress 19147209 Y 11/2015 Initiation 11% - -
FDA (NDA 
21–785)
Fulvestrant
Estrogen 
receptor
22896656 Y 1/2021 Initiation 68% 10%
FDA (NDA 
21–344)
L-asparaginase Glycosylation 22333033 Y No patent Initiation 28% 5%
FDA (125359 
Orig1s000)
Suberoylanilide 
hydroxamic 
acid
HDAC 21491416 Y 2/2025 Initiation 58% 4%
FDA (NDA 
21–991)
Bafilomycin Lysosome 22564965 N - Clearance - - -
SB202190 MAPK 21853067 N - Clearance - - -
Decitabine Methylcytosine 21491416 Y Equivalents Initiation - 27% 93%
16532500 and 
FDA 
(NDA 205582)
Paclitaxel Microtubules 22430212 Y Equivalents Initiation - 46%
FDA (NDA 
20–262/ 
S-024)
Wortmannin PI3K 21853067 N - Initiation (toxic)
PMID 
2527336
(Continued )
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observed. Interestingly, the addition of rapamycin to 
other autophagy-initiating agents produced significantly 
additive effect on cell death (Figure 3A, 3B). Similar 
results were obtained when chloroquine was combined 
with these agents (Figure 3C, 3D), raising the notion that 
autophagy occurred in response to an autophagic stress 
on the cells.
Higher order combinations of the five drugs 
produced, in general, increasing efficacy (Figure 3E). 
However, the combination of chloroquine and nelfinavir 
(CN) was also among the most potent at inducing cell 
death, and the only two-drug combination found to do 
so in a 48 hour time-frame. Nonetheless, immunoblot 
analysis of LC3-II levels at 24 hours proved a reasonable 
surrogate of cell death at 48 hours (Figure 3F); peaking in 
those combinations that had maximal cytotoxic activity. 
Similar efficacy was found in other SOC models ID8ip, 
OVCAR8, and PS#3971, and did not depend on cisplatin 
sensitivity (Supplementary Figure S1).
Combinatorial autophagic stresses enhance 
LC3 and p62 punctae
To evaluate whether LC3-II accumulation 
corresponded to the presence of autophagosomes, we next 
stained cells to evaluate the relocalization of LC3 from 
diffuse cytosolic distribution to punctae indicative of 
autophagic vesicles. Following treatment with the panel of 
agents, alone (Figure 4A) or in combination (Figure 4B), 
we found that the relative measure of LC3 positive punctae 
was in agreement with the immunoblot data.
In parallel, we evaluated the presence of p62/
sequestosome as a reporter of the cell’s sensation of 
proteotoxic stress. Autophagy normally clears p62 
when functioning properly, however stress that induces 
autophagy also induces p62 expression [14, 28]. 
Punctate p62 can therefore indicate an over-stressed 
autophagy system [29]. Nelfinavir or chloroquine 
treatment elevated punctate p62, while rapamycin and 
dasatinib had a more modest effect, and metformin 
slightly reduced p62 but did not alter punctate LC3 
compared to controls. However, when drugs were used 
together, p62 accumulated, suggesting the presence of 
an ongoing, unrelieved proteotoxic stress despite the 
overt induction of autophagy. The p62 and LC3 punctae 
reached a maximum signal upon treatment with all five 
autophagy drugs, which we term for simplicity Necramed 
(Nelfinavir, chloroquine, rapamycin, metformin, and 
dasatinib).
To further test the quality of autophagy, we used 
a dual labeled mCherry-GFP-LC3 reporter system 
[30]. Autophagolysosome formation quenches the GFP 
signal due to acidification, which mCherry is resistant 
to and remains fluorescing red. Yellow punctae thus 
primarily represent autophagosome structures which 
have not successfully fused with functional lysosomes 
and therefore have not cleared enclosed damaged 
organelles and proteins. As expected with a drug 
combination containing chloroquine, LC3 punctae 
using this reporter were primarily yellow, stalled 
autophagosomes, which accumulated during Necramed 
treatment (Figure 4C).
Evaluation of combinations of cell stressors 
in vivo
Given that the cytotoxicity in vitro was similar 
between all five autophagy drugs and the simple 
combination of chloroquine and nelfinavir (Figure 3E), 
despite apparent differences in proteotoxic stress induced 
in the cells, we wondered whether these two approaches 
might act similarly in vivo. To test this, the syngeneic, 
ID8ip-mCherry [19] cell model was used. The literature on 
the doses of these autophagic drugs to use in vivo varies, 
Most Frequent 
Adverse Events
Drug Target Ref 
(PMID)
FDA 
approved?
Patent end 
date?
Autophagy 
stage
G1–2 G3 G4 Safety 
Reference
Notes
Bortezomib Proteasome 19584239 Y 10/2014
Proteasome 
disruption
100% 61% 14%
FDA (NDA 
21–602)
MG132 Proteasome 23270461 N -
Proteasome 
disruption
- - -
H2O2 ROS 23047606 N - Initiation - - -
FTY720 S1P receptor 20935520 Y 2/2019
Initiation, 
siBECN1 and 
siLC3 block 
effect
9% - -
FDA (NDA 
22–527)
Arsenic trioxide Unknown 22919067 Y 11/2018
Initiation (less 
pAkt)
75% 13%
FDA (NDA 
21–248)
Withafarin A Vimentin 22860102 N - Initiation - - -
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so we opted to use a standard, FDA recommended method 
of mouse-human dose adjustment calculations [31] which 
focuses on surface area, blood physiology, and metabolism 
(Table 3). In this case, peritoneal tumors were allowed to 
develop for two weeks, and then mice were treated daily 
with control solution, chloroquine and nelfinavir (CN), or 
with the combination of all five agents (Necramed) for 14 
days. Interestingly, and despite the fact that these regimens 
yielded similar efficacy in vitro (Figure 3E), there was a 
marked difference in vivo (Figure 5A). Tumors could be 
macroscopically detected in the CN group, and did not 
significantly differ than those from untreated control mice. 
In dramatic contrast, there were no macroscopic tumors 
detectable in the Necramed group, although 1/8 mice 
Figure 1: Strategy for pathway-based in silico drug selection. (Left) Diagram outlining how many drugs were within each step 
of the drug selection process. The last filter selected a single drug from each mode of action based on documented minimal adverse events. 
(Right) Model of potential interactions between autophagy, autophagy drugs, and the cell death pathways necroptosis and apoptosis.
Table 2: Patient blood levels of autophagic drugs
MW Peak Molarity Trough Molarity Reference 
(PMID)
Metformin 165.62 1600 ng/mL 9.66E-06 273 ng/mL 1.65E-06 22864111
Chloroquine 515.86 4500 ng/mL 8.76E-06 600 ng/mL 1.16E-06 3289601
Nelfinavir 663.89 3820 ng/mL 9.94E-06 125 ng/mL 3.27E-07 NDA 21-503
Rapamycin 914.2 30 ng/mL 1.15E-07 23 ng/mL 8.80E-08 9721433
Dasatinib 488.1 129 ng/mL 2.64E-07 8.7 ng/mL 1.78E-08 22837181
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Figure 2: Autophagy drugs act independently of apoptosis and necroptosis. A. Comparison of LC3-II immunoblot levels 
to %Cell Loss. Doses were: chloroquine (C, 10 μM), nelfinavir (N, 10 μM), rapamycin (R, 10 nM), dasatinib (D, 100 nM), metformin 
(M, 10 μM). P value is a Pearson’s correlation test. B–E. Immunoblots of OVCAR3 cells treated for 24 hours with the indicated drugs. 
The necroptosis positive control is OVCAR3 cells treated with Birinapant and z-VAD
fmk
 (20 μM). The apoptosis positive control is 293T 
cells treated with cisplatin at 10 μM. PARP* indicates cleaved PARP, PARP-FL indicates full length PARP. pMLKL is pS358-MLKL. 
F–J. Crystal violet proliferation assay of OVCAR3 cells grown for 48 hours in the presence of the indicated drugs. %Cell Loss indicates 
difference of treated cells to that of untreated, maximally proliferating controls. Nec-1, necrostatin, was used at 30 μM. *p < 0.05, by t-
test to autophagy drug of same dose. (F) Control crystal violet proliferation assay done within the same assays as other cell loss panels, 
where IAP Ant is the SMAC mimetic Birinapant at 100 nM, which produces necroptosis when caspases are inhibited by z-VAD
fmk
, and the 
necroptosis can be suppressed by addition of Nec-1. ***p < 0.001 by t-test. All error bars are s.e.m.
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Figure 3: Autophagy aggravation and inhibition increase cell loss in combination therapy. A–D. Crystal violet 
proliferation assay of OVCAR3 cells grown for 48 hours in the presence of the indicated drugs. %Cell loss indicates difference of 
treated cells to that on untreated, maximally proliferating controls. +/– Rapa indicates the presence of rapamycin dosed at 100 nM. 
+/– CQ indicates chloroquine added at 5 μM. **p < 0.01, ***p < 0.001 by one-sample t-test comparing the difference of the drug pair 
and the most active single drug to the null difference of zero. E. Two day crystal violet proliferation assay depicting a fully factorial 
combination screen for the five autophagy drugs metformin (M, 10 μM), rapamycin (R, 10 nM), dasatinib (D, 50 nM), chloroquine 
(C, 9 μM), and nelfinavir (N, 9 μM). Doses represent peak (M,C,N) or trough (R,D) drug concentrations found in patient blood levels. 
Cisplatin (CP, 5 μM) was also used for comparison. n.s. indicates sample comparisons are p > 0.05 by student’s t-test. All error bars 
are s.e.m. F. Immunoblot of OVCAR3 cells treated with the indicated drugs for 24 hours. Doses were R 100 nM, N 5 μM, C 2.5 μM, 
D 100 nM, and M 10 μM, chosen for their dynamic range.
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Figure 4: Measurement of dysregulated autophagy by fluorescent microscopy. OVCAR3 cells were treated with the indicated 
drugs for 24 hours and then fixed and immunostained for p62 (red) and LC3 (green), with a DAPI costain (blue). Confocal z-stacks were 
flattened for image analysis to capture all punctate area. A. Doses were: chloroquine (10 μM), nelfinavir (10 μM), rapamycin (10 nM), 
dasatinib (50 nM), and all were combined for Necramed. B. Similar immunostaining as in (A) Punctae were quantified for size and 
number per cell by ImageJ with at least 40 cells per condition. LC3 channel was analyzed for autophagosomes, and the p62 channel for 
sequestosomes. Doses were same as in (A), but with chloroquine and nelfinavir reduced to 5 μM. *p < 0.05, ***p < 0.001 by t-test. All error 
bars are s.e.m. C. OVCAR3 cells with a virally integrated mCherry-GFP-LC3 construct were studied by live microscopy, for the number 
of hours indicated following Necramed (doses as in (A)) or control treatment.
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had a residual island of cells microscopically detectable 
on an ovary (1.7 mm3, Figure 5A). There were no overt 
indications of toxicity either by gross visual examination 
or by weight loss in either the CN or Necramed groups 
(Figure 5B). Consistent with the initial screening strategy 
to select drugs with minimal adverse effects (Figure 1) 
there were no gross histological changes in Necramed-
treated mice (Supplementary Figure S2). Finally, no signs 
of toxicity in blood panels were observed in Necramed-
treated mice relative to untreated mice (Supplementary 
Table S1). Thus, despite a potent anti-tumor activity, no 
overt systemic toxicity was associated with Necramed 
treatment.
LC3-II is detected in tumors treated with the 
necramed combination
A problem with the observed efficacy was that 
it did not permit the evaluation of LC3-II increases 
with treatment, as there were no substantial tumors left 
amenable to immunoblot analysis. To remedy this and test 
another tumor model, we next treated mice with Necramed 
in which we titrated nelfinavir to 5% (25 mg/kg, 1/10th 
the ID8ip model dose) of a dose converted from human 
use into a mouse dose [31], following seeding with the 
human PS#3971 tumor model. The reduced-nelfinavir 
combination impacted the distribution of tumors in vivo 
(Figure 5C) but enough tumor remained to allow for 
detection of increased LC3-II/β-actin in treated mice 
(Figure 5D). Altogether, the results supported the notion 
that LC3-II acted as a reporter for Necramed activity.
DISCUSSION
We find that a patient-data centered screen of 
previously studied drugs with documented evidence of 
affecting a defined pathway in ovarian cancer permits 
one to derive a safe and efficacious combination. Here, 
agents were not selected based on a history of oncologic 
use, but rather on reported alteration of autophagy. Our 
data supports a limited impact of single agents, since even 
the best two agents combined lacked significant effect in 
our aggressive mouse model. In contrast, reducing one 
effective component from 250 mg/kg to 25 mg/kg retained 
significant activity when used as part of the five drug 
combination therapy.
The agents that came through the screen are varied 
in targets and function. Dasatinib, originally designed 
as an inhibitor of Bcr-Abl, also targets tyrosine kinases 
such as Src which act upstream of Akt and mTOR [16] 
(Supplementary Figure S3). Rapamycin, which failed 
as a cancer monotherapy, acts proximal to the Becn1/
Ulk1/Vps34 autophagy initiation complex by inhibiting 
mTORC1 [32]. The other agents are rarely or never 
indicated for cancer therapy. Nelfinavir is an inhibitor 
of HIV-1 protease [33], but induces ER stress [34, 35], 
reduces proteasome function [36], and may weakly inhibit 
an array of kinases including Akt [37]. Metformin is 
used in diabetes mellitus; it is thought to trigger AMPK 
upstream of the Becn1/Ulk1/Vps34 complex [38], though 
it has additional metabolic effects [39] that may impact 
stem cells [40] and contribute to its documented capacity 
to improve survival of ovarian cancer patients [41]. 
Chloroquine is unique in its capacity to block autophagy. 
More specifically, it blocks late events, preventing fusion 
of autophagosomes with lysosomes and autophagic 
‘flux’ [42, 43]. Developed as an antimalarial, it has been 
used in a small number of cancer clinical trials [44], and 
derivatives of chloroquine are currently of interest in a 
number of cancers.
Although drug combinations are routinely 
prescribed in antimicrobial applications, oncologists 
Table 3: Human to mouse dose conversions
Drug Human 
mg/kg*
Human 
Reference
Mouse 
mg/kg**
Necramed 
mg/kg (mouse)
Mouse 
reference
Reference mouse 
dose (mg/kg)
Metformin 16.7
Metformin 
OvCa clinical 
trial
205.6 150
PMID 
22864111
150
Chloroquine 8.3
PMID 
19326448
102.8 30
PMID 
19033662
50
Nelfinavir 41.7 Drugs@FDA 513.9 500 (100%)
PMID 
22664238
5
Rapamycin 0.3
PMID 
22872575
3.3 2.24
PMID 
23014526
10
Dasatinib 1.7 Sprycel dockets 20.6 4
PMID 
20629079
10
*All human mg/kg are from oncology clinical trials, except for Nelfinavir
**Dose conversions from human mg/kg, using calculation from reference PMID 17942826 
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avoid combinations in cancer chemotherapy, since they 
frequently involve pushing the limits of toxicity in the 
attempt to eradicate cancer and may not offer further 
benefit [45] if their mechanism of action is similar. 
Therefore, to best allow for combining these agents with 
minimal chance of detrimental side effects, we focused 
this screen on those drugs with the lowest number and 
severity of adverse event reports. Consistent with this, 
we did not observe systemic toxicity, even in mice treated 
with all five agents. In retrospect, this is perhaps not 
surprising; a ‘typical’ cancer patient is associated with an 
aging demographic that frequently takes medications for 
one, or many, unrelated non-oncologic indications.
This screen targeted drugs that modulate autophagy, 
which is considered both a cancer cell survival factor 
[46, 47] and drug resistance [15] factor in ovarian cancer. 
Although we induce autophagosome formation, it does not 
appear to be the instrument of cell death. In fact, we make 
the distinction that arresting autophagy did not ameliorate 
death, but rather enhanced it (Figure 3). Together with prior 
data, this supports the concept that autophagy may represent 
a mechanism by which tumor cells resolve inherent or 
Figure 5: Autophagy combination therapy suppresses SOC in vivo. A. C57BL/6 immunocompetent mice were injected 
IP with 3 × 106 ID8ip-mCherry cells. After two weeks, mice were orally gavaged daily with control, Necramed, or with chloroquine 
(C) and nelfinavir (N) only. Following two weeks of treatment, mice were euthanized and mCherry fluorescent tumors quantified. B. The 
weight profiles of mice in (A) Error bars are s.e.m. C. A patient derived xenograft model, using ascites cells from a recurrent platinum-
insensitive patient, was established by injecting 3 million PS#3971 cells IP into nude mice. One week following injection, mice were 
gavaged daily with control or 5%N Necramed (Nelfinavir reduced to 25 mg/kg), for 32 days. Mice were euthanized and macroscopic 
tumors dissected and weighed. Wilcoxon rank sum test was used to statistically compare groups. D. Immunoblots of pooled tumors 
dissected from each mouse in (C).
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induced stresses [48, 49]. Thus, combining agents which 
initiated cell stresses that activate autophagy with one that 
blocked resolution of autophagy acted cooperatively to 
kill cells (Figure 6). In our study, we found no evidence 
of apoptosis or necroptosis. Considering that resistance 
to apoptosis is a common hallmark of cancer [50] it may 
be that alternative mechanisms of cytotoxicity, such as 
proteotoxicity, are worth considering in a therapeutic 
context.
Can these results translate into the clinic? The focus 
on limited adverse events based on existing patient data, 
some from very large cohorts [51], appears promising for 
the perspective of a Phase I trial. Hesitation to use drug 
combinations is waning. Doxorubicin is a standard second/
third line treatment for SOC, usually given in a less toxic 
pegylated liposomal form as Doxil®, and has been used in 
combination with anti-HIV HAART therapy for Kaposi’s 
sarcoma. HAART typically consists of a minimum of a 
three drug combination and has included Nelfinavir. Doxil®, 
with its standard use and relatively favorable side effect 
profile, may be an ideal candidate for the chemotherapy 
which uses Necramed in an adjuvant setting.
How might Necramed itself be administered? We 
delivered all drugs by gavage, since in human patients 
all drugs are delivered orally. Theoretically, a slight delay 
in the administration of chloroquine might optimize 
the effects of the other collaborative, stress-inducing 
agents. However, we co-administered all drugs, at least 
initially, to simplify patient compliance and adherence. 
Since concomitant dosing of all drugs was successful and 
tolerable in our mouse models, simultaneous dosing is a 
viable clinical option. Drug dosage can be immediately 
reduced within individual patients if side effects are 
limiting, as may be determined in a Phase I clinical trial. 
Given the daily loss of more than three dozen women in 
the US to ovarian cancer, the risk of avoiding efficacious 
combination therapies is very high, and can outweigh the 
potential risks of combinatorial side effects.
MATERIALS AND METHODS
Reagents
 All cells were grown in RPMI (Life Technologies) 
supplemented with 2 g/L glucose, nonessential amino 
acids, sodium pyruvate, and 10% FBS (Omega 
Scientific). Cells were always incubated at 37°C in a 
water jacketed incubator with 5% CO2. Antibodies. For 
Figure 6: Model for dysregulated autophagy mediated proteotoxicity in ovarian cancer. 
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western blots, Actin (Sigma #A5441-.2ML), LC3 (Novus 
Biologicals #NB100-2220), PARP (BD Biosciences 
#51-6639GR), pS358-MLKL (abcam #ab187091) were 
used. Secondary HRP-conjugated antibodies were anti-
rabbit (Jackson ImmunoResearch #211-032-171) anti-rat 
(Life Technologies #619520), or anti-mouse (Jackson 
ImmunoResearch #115-035-003). Drugs. Cisplatin (Teva 
Pharmaceuticals, US, 1 mg/ml injectable) was obtained by 
the Moores Cancer Center pharmacy. Metformin (VWR, 
cat# 89147-892), chloroquine phosphate (Fisher Scientific, 
ICN19391910), rapamycin (LC Labs, cat# R-5000), 
dasatinib (LC Labs, cat# D-3307), and nelfinavir mesylate 
(Creative Dynamics Inc, special order except in syngeneic 
mouse model, which used pulverized Viracept tablets 
obtained from the Moores Cancer Center pharmacy) were 
purchased in powdered form. PEG400 for in vivo drug 
vehicle was from Spectrum Laboratory Products (#TCI-
N0443-500G) and mixed with sterile saline (Teknova, 
#S5812). Patient consent was obtained for scientific use 
and publication of the OV#3971 patient derived ovarian 
cancer [18].
Crystal violet proliferation assays
Cells (2,500–5,000/well) were seeded onto 96 well 
TC treated plates, allowed to attach, and then treated 
with drugs or control vehicle in a total volume of 100 μl. 
Plates were placed at 37°C for 48 hours (unless otherwise 
indicated). Media was removed and cells were washed 
once with 125 μl PBS. PBS was then removed and 50 μl 
crystal violet stain (0.11% crystal violet, 0.17M NaCl, 
22% MeOH, in water) was added. After 30 minutes 
room temperature staining, stain was removed and 
125 μl PBS was added as a wash. Supernatant was 
carefully removed to minimize cell disturbance but 
maximize removal of unbound crystal violet. Plates 
were then dried at 37°C for one hour without lid and 
85 μl MeOH was added to solubilize the crystal violet. 
Absorbance was read at 600 nm to determine cell density. 
Percent growth inhibition (%Cell Loss) was calculated 
using the formula: 100-(100*AbsDrug/AbsControl). This 
reflects loss from either death or impaired proliferation.
Western immunoblotting
Cells (3 × 106) were seeded on 10 cm plates, allowed 
to adhere for 16–24 hours, and treated with drugs or 
control for 24 hours at 37°C. 300–400 μl iced RIPA buffer 
(supplemented with a protease inhibitor cocktail (Sigma-
Aldrich), 2 mM sodium orthovanadate, and 50 mM NaF) 
was added to lyse the cells (15 minutes, room temperature) 
at which point cells were collected using a cell lifter (Fisher 
Scientific). Lysates were spun at 10,000 g for 10 minutes 
at 4°C and supernatant saved and quantified by BCA assay 
(Pierce #23235). 30 μg protein was loaded per well of a 15% 
SDS-PAGE gel and transferred onto a PVDF membrane. 
Membrane was blocked in 5% dry milk (Genesee Scientific, 
#20-241). Primary antibodies were used at 1:1000 dilution, 
and secondary HRP-conjugated antibodies were used at 
1:5,000 dilution. HRP substrate and enhancer was used at 
600 μL per membrane (Super Signal West Dura Extended 
Duration Substrate, Pierce # 34075).
Immunofluorescence
Coverslips coated with 2 μg/ml fibronectin were 
placed into non-TC treated 6 well plates. Excess fibronectin 
was removed with PBS washes. 10,000 cells were seeded 
directly onto the coverslip and allowed to adhere for 
30 minutes at 37°C. Media with drugs or vehicle was then 
added to a total volume of 3 ml. Cells were incubated 
at 37°C for 24 hours. Media was removed and 1 ml 4% 
paraformaldehyde in PBS was added for 15 minutes at 
room temperature. Supernatant was aspirated and cells were 
washed once with PBS. PBS was aspirated and 2 ml 0.1% 
Triton in PBS was added for intracellular permeabilization. 
After 2 minutes, supernatant was aspirated and PBS 
wash performed. Cells were then blocked in 2% BSA for 
30 minutes at room temperature and then a PBS wash 
performed. Primary antibodies were then added in 2% 
BSA (1:1000 dilution for LC3, 1:500 dilution for p62) and 
incubated for 90 minutes at room temperature. After three 
PBS washes, secondary antibodies were added in 2% BSA 
with DAPI (1.5 μg/ml) at a 1:1000 dilution for 90 minutes. 
Three more PBS washes were performed, and then one 
final ten minute PBS wash performed. PBS was aspirated 
and coverslips were mounted on glass slides using 30 μl 
Vectashield (Vector Laboratories #H-1400). Cells were 
imaged on a Nikon confocal microscope, creating z-stacks 
to permit punctae quantitation. Flattened z-stacks were used 
to quantify punctae in ImageJ by MaxEntropy thresholding.
Autophagic flux microscopy
OVCAR3 cells with mCherry-GFP-LC3B 
(Addgene, plasmid # 22418) retroviral integrants were 
seeded (100 k cells) on a 12 well fibronectin treated (2 μg/
ml) glass bottom plate and allowed to adhere overnight. 
Fields of view were set on an Olympus IX51 microscope 
outfitted with an environmental apparatus allowing for 
tissue culture (37°C and 5% CO
2
) conditions. Drugs 
were added and then cells imaged for mCherry and GFP 
fluorescence every 4 hours.
Mouse cancer models
All animal protocols were approved by the UCSD 
IACUC; appropriate regulations were followed during 
experimentation on animals. Syngeneic model: 3 × 106 
mCherry labeled ID8ip cells [19], which have been 
passaged in the peritoneal cavity, were injected into 
syngeneic female C5BL/6 mice at 10 weeks of age. Eight 
mice of equal mean weights were used in each group. 
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14 days after injection, the control group received daily 
(7x/week) vehicle gavage injections (50% PEG400), 
the CN group received daily gavages of chloroquine 
(30 mg/kg) and nelfinavir (250 mg/kg, from pulverized 
Viracept tablets) in 50% PEG400, and the Necramed 
group received daily gavages of chloroquine (30 mg/
kg), nelfinavir (250 mg/kg), rapamycin (2.24 mg/kg), 
metformin (150 mg/kg), and dasatinib (4 mg/kg) in 
50% PEG400. Mice were monitored daily for distended 
abdomens following the first treatment injections. All 
mice were euthanized when ascites formation produced 
visible discomfort to control animals, which occurred 
after 14 days of treatment (28 days since cell injection). 
The peritoneum of the mice was exposed and any visible 
nodules on the peritoneum wall were surgically dissected 
along with the liver and ovaries. These tissues were then 
imaged with the OV100 Small Animal Imaging System 
(Olympus). Brightfield, GFP, and mCherry channel 
information were collected and only red fluorescent (but 
not green autofluorescent) punctae area was quantified in 
ImageJ. Fluorescent area was mathematically converted 
into tumor volume assuming spherical shape of the 
tumor and circular shape of the fluorescent area with 
the equations: area = πr2 and volume = 4π/3r3. Recurrent 
platinum resistant intraperitoneal low passage patient 
derived model: PS#3971 cells were isolated from a 
patient’s ascites with recurrent SOC. The patient failed 
the next round of platinum therapy, and her cells were 
verified to be platinum resistant (Supplementary Figure S1). 
Cells were grown in standard adherent tissue culture 
conditions until a sufficient number of cells was obtained 
(<5 passages). Mice were randomized into equal weight 
groups. Three million PS#3971 cells were injected IP into 
nude mice, allowed to disseminate and grow for 7 days, 
and then daily gavaging and weighing began. Necramed 
(150mg/kg metformin, 50 mg/kg chloroquine, 25 mg/kg 
[5% human-mouse converted dose equivalent] nelfinavir, 
2.25 mg/kg rapamycin, and 10 mg/kg dasatinib, in 
50% PEG400/saline) or control (50% PEG400, 50% 
saline) gavaging was performed for 32 days. Mice 
were euthanized and visible tumors were harvested, 
photographed, weighed, and lysed for immunoblotting.
Mouse safety models
Control (gavage, daily, 50% PEG400) or Necramed 
(chloroquine (30 mg/kg), nelfinavir (250 mg/kg), 
rapamycin (2.24 mg/kg), metformin (150 mg/kg), and 
dasatinib (4 mg/kg) in 50% PEG400, gavage, daily) 
treatment began at 10 weeks of age. For histology, 
nude mice were treated for 7 days and then euthanized 
3 hours following the last treatment. Liver, heart, and 
kidneys were harvested, fixed in 10% buffered formalin 
for 24 hours and then 70% ethanol for at least 24 hours, 
blocked, sectioned with 3 μm width, and H&E stained 
by the core facility at the Moores Cancer Center. 
Histology images were taken with a 4X objective on 
a Nikon Eclipse TE2000E inverted microscope. An 
additional 3 pairs of C57BL/6 mice were treated with 
control or Necramed for 21 days, sacrificed, and blood 
collected immediately by cardiac extraction. Blood was 
centrifuged in a Micro Serum Separator (Professional 
Hospital Supply) and plasma saved in a microcentrifuge 
tube at –20°C until analysis by a VetScan instrument 
using a VS Complete Diagnostic Profile.
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